Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which ...

Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality ...

Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Sanofi S.A. (Paris, France) and Blueprint Medicines Corp. (Blueprint), a U.S.-based, publicly traded biopharmaceutical company specializing in systemic ...

This type of systemic mastocytosis occurs when the excessive growth of mast cells is combined with another blood disease, such myeloproliferative disorder (a condition in which the bone marrow ...

Although clear areas of overlap are known to exist between mast cell disorders and eosinophilia, it is seemingly easier to navigate each of these disease entities separately—that is, to address mast ...

Mast cell activation syndrome, or disease (MCAS), is a condition that causes mast cells to release these substances too frequently, resulting in severe allergic reactions. After detecting an ...

These skin manifestations sometimes provide the most visible evidence of mast cell dysfunction, though they may be absent in some patients whose symptoms predominate in other body systems.

The disease course is highly variable ... 1 Pathogenesis of CSU: The Role of Mast Cells Understanding the role of mast cells is key to grasping the underlying mechanisms of CSU.